Michael A. Metzger, Chief Executive Officer at Syndax Pharmaceuticals Inc (SNDX), sold 63,204 shares at $21.06 ($1.3M) on 2022-07-25, disclosed to the SEC on 2022-07-27.
Open-market sale of $1.3M SNDX by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.06 | 11,838 | $249K | 18.7% |
| 2 | $21.06 | 11,838 | $249K | 18.7% |
| 3 | $21.06 | 19,764 | $416K | 31.3% |
| 4 | $21.06 | 19,764 | $416K | 31.3% |
| Total | $21.06 avg | 63,204 | $1.3M | 100% |
| Filing → |
| SNDX | SELL | 2026-02-10 | $361K | — | Filing → |
| SNDX | SELL | 2026-02-06 | $153K | — | Filing → |
| SNDX | SELL | 2025-09-08 | $5.2M | — | Filing → |